Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution
Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid h...
Saved in:
Published in | Metabolites Vol. 14; no. 10; p. 565 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
01.10.2024
MDPI |
Subjects | |
Online Access | Get full text |
ISSN | 2218-1989 2218-1989 |
DOI | 10.3390/metabo14100565 |
Cover
Abstract | Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients. |
---|---|
AbstractList | Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).
Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.
Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL;
= 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy.
Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients. Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).BACKGROUND/OBJECTIVESFibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto's thyroiditis (HT).Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.METHODSEighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay.Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy.RESULTSMedian serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4-148.3) pg/mL vs. 131.9 (44.8-236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy.Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients.CONCLUSIONSOur results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients. Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on the blood vessels, liver, and adipose tissues. We aimed to investigate serum FGF21 level and its relation to thyroid hormones and metabolic parameters among patients with Hashimoto’s thyroiditis (HT). Methods: Eighty patients with HT on levothyroxine treatment and eighty-two age- and BMI-matched adults without thyroid disease serving as controls were enrolled. Serum FGF21 concentrations were determined with an enzyme-linked immunosorbent assay. Results: Median serum FGF21 level was significantly lower in HT patients compared with controls (74.2 (33.4–148.3) pg/mL vs. 131.9 (44.8–236.3) pg/mL; p = 0.03). We found a positive correlation between FGF21 and age, triglyceride, total cholesterol, and low-density lipoprotein cholesterol in both groups, while thyroid stimulating hormone and C-reactive protein showed a positive correlation, and thyroxine had an inverse correlation with FGF21 only in control subjects. According to multiple regression analyses, thyroid status is the main predictor of FGF21 in healthy controls, while it is not a significant predictor of FGF21 among HT patients on levothyroxine supplementation therapy. Conclusions: Our results indicate that the physiological role of thyroid function in the regulation of FGF21 synthesis is impaired in HT patients, which may contribute to the metabolic alterations characteristic of HT patients. |
Audience | Academic |
Author | Csiha, Sára Lőrincz, Hajnalka Somodi, Sándor Bodor, Miklós Halmi, Sándor Bhattoa, Harjit Pal Harangi, Mariann Hutkai, Dávid Nagy, Endre V. Berta, Eszter Paragh, György Molnár, István Katkó, Mónika |
AuthorAffiliation | 6 Kálmán Laki Doctoral School, University of Debrecen, H-4032 Debrecen, Hungary 1 Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; lorincz_hajnalka@belklinika.com (H.L.); somodi@med.unideb.hu (S.S.); harangi.mariann@med.unideb.hu (M.H.); paragh.gyorgy@med.unideb.hu (G.P.) 4 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; katko.monika@med.unideb.hu (M.K.); endrenagy@med.unideb.hu (E.V.N.) 2 Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary; csiha.sara@med.unideb.hu (S.C.); bodor.miklos@med.unideb.hu (M.B.) 5 Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; hutkai.david@med.unideb.hu 3 Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary; halmi.sandor@med.unideb.hu (S.H.); d |
AuthorAffiliation_xml | – name: 8 Department of Emergency Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary – name: 4 Division of Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; katko.monika@med.unideb.hu (M.K.); endrenagy@med.unideb.hu (E.V.N.) – name: 6 Kálmán Laki Doctoral School, University of Debrecen, H-4032 Debrecen, Hungary – name: 2 Department of Clinical Basics, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary; csiha.sara@med.unideb.hu (S.C.); bodor.miklos@med.unideb.hu (M.B.) – name: 3 Doctoral School of Health Sciences, University of Debrecen, H-4032 Debrecen, Hungary; halmi.sandor@med.unideb.hu (S.H.); dr.molnar.istvan@med.unideb.hu (I.M.) – name: 7 Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; harjit@med.unideb.hu – name: 5 Division of Nephrology, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; hutkai.david@med.unideb.hu – name: 1 Division of Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Debrecen, H-4032 Debrecen, Hungary; lorincz_hajnalka@belklinika.com (H.L.); somodi@med.unideb.hu (S.S.); harangi.mariann@med.unideb.hu (M.H.); paragh.gyorgy@med.unideb.hu (G.P.) |
Author_xml | – sequence: 1 givenname: Eszter orcidid: 0000-0003-0439-9867 surname: Berta fullname: Berta, Eszter – sequence: 2 givenname: Sándor surname: Halmi fullname: Halmi, Sándor – sequence: 3 givenname: István surname: Molnár fullname: Molnár, István – sequence: 4 givenname: Dávid surname: Hutkai fullname: Hutkai, Dávid – sequence: 5 givenname: Sára surname: Csiha fullname: Csiha, Sára – sequence: 6 givenname: Harjit Pal orcidid: 0000-0002-4909-0065 surname: Bhattoa fullname: Bhattoa, Harjit Pal – sequence: 7 givenname: Hajnalka orcidid: 0009-0000-5303-3082 surname: Lőrincz fullname: Lőrincz, Hajnalka – sequence: 8 givenname: Sándor surname: Somodi fullname: Somodi, Sándor – sequence: 9 givenname: Mónika orcidid: 0000-0002-9791-9288 surname: Katkó fullname: Katkó, Mónika – sequence: 10 givenname: Mariann orcidid: 0000-0001-9761-9595 surname: Harangi fullname: Harangi, Mariann – sequence: 11 givenname: György surname: Paragh fullname: Paragh, György – sequence: 12 givenname: Endre V. orcidid: 0000-0002-9286-6471 surname: Nagy fullname: Nagy, Endre V. – sequence: 13 givenname: Miklós surname: Bodor fullname: Bodor, Miklós |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39452947$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkstuEzEUhkeoiJbSLUtkiQ2btLZnxp5ZoapqmkiRQLSsLdtzJnE0Ywfb05Adr8GaN-NJcJregpCwF7aO__P53F5nB9ZZyLK3BJ_meY3PeohSOVIQjEtWvsiOKCXViNRVffDsfpidhLDEaTFcckxeZYd5XZS0LvhR9mvm1uga_NCjsVHeqU6GiK68W8cFGksdnUeUoBncQoekbdA0BnTeRfDQoC8wHzoZjbNIbdDNYuOdadDE-T7FGZCx6HN6BZtc1ibxJjIsTO-i-_3jZ3jQm2gCSoT0hYtb03djAV0PKkQThy38TfaylV2Ak_vzOPs6vry5mIxmn66mF-ezkS4xj6OaaVxAq2gu21oTWVHATOaFqmihS8IU1rhSlLU1pxRzxYmWikuuMVayaar8OJvuuI2TS7Hyppd-I5w04s7g_FxIH43uQFSgFTRc16ViBbBcKlxDxTHmoLDUNLHOdqzBruRmLbvuEUiw2HZP7HcveXzceawG1UOjU9m87PbC2H-xZiHm7lYQUuLUT5YIH-4J3n0bIETRm6Ch66QFNwSRE5pGALN8G977v6RLN3ibqnun4kXBOH9SzWXK2djWpY_1FirOK1IUmDCKk-r0H6q0G-iNTpPQmmTfc3j3PNPHFB-m8omovQvBQ_u_2v0BAcf4Og |
Cites_doi | 10.1038/ncomms3019 10.1530/EC-18-0272 10.1111/j.1365-2826.2012.02383.x 10.3389/fimmu.2019.02349 10.1016/j.intimp.2018.01.048 10.1007/s00011-019-01222-2 10.4103/japtr.JAPTR_298_18 10.1016/j.jdiacomp.2016.10.017 10.3389/fneur.2017.00079 10.3390/medicina57121374 10.1530/EJE-22-0247 10.4103/ijem.IJEM_273_19 10.3389/fendo.2022.915394 10.1016/j.ejim.2016.03.028 10.2337/db11-0672 10.3389/fendo.2022.873699 10.1007/s12020-014-0502-9 10.1038/jhh.2012.52 10.1530/EJE-15-1061 10.1016/j.xcrm.2024.101629 10.1507/endocrj.EJ12-0427 10.3389/fendo.2023.1187725 10.1210/me.2010-0142 10.1074/jbc.C110.107375 10.1530/JOE-14-0440 10.2337/db07-1476 10.1186/1471-2458-7-220 10.1016/j.metabol.2009.07.003 10.1161/ATVBAHA.113.301599 10.15212/FMCH.2014.0118 10.1016/j.metabol.2021.154738 10.1210/en.2013-1902 10.3389/fpubh.2022.1020709 10.1210/jc.2015-1797 10.1210/er.2018-00163 10.1007/s12020-020-02484-1 10.1210/er.2008-0019 10.1080/0886022X.2023.2179336 10.1016/j.tem.2019.05.007 10.1111/j.1365-2265.2008.03502.x 10.1055/a-1778-4159 10.1373/clinchem.2010.155184 10.3389/fendo.2018.00800 10.1371/journal.pone.0129791 10.3390/biomedicines12061320 10.1186/1475-2840-12-124 10.1194/jlr.M051664 10.3390/cancers11081154 10.1172/JCI23606 10.21037/apm-21-525 10.2337/db18-1806-P 10.1007/s10753-017-0665-7 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024 |
Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024 |
DBID | AAYXX CITATION NPM 7QR 8FD 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 GNUQQ HCIFZ LK8 M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM ADTOC UNPAY DOA |
DOI | 10.3390/metabo14100565 |
DatabaseName | CrossRef PubMed Chemoreception Abstracts Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One ProQuest Central Korea Engineering Research Database ProQuest Central Student SciTech Premium Collection Biological Sciences Biological Science Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) Unpaywall for CDI: Periodical Content Unpaywall DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Natural Science Collection ProQuest Central Korea Biological Science Collection Chemoreception Abstracts ProQuest Central (New) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition Biological Science Database ProQuest SciTech Collection Biotechnology and BioEngineering Abstracts ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: UNPAY name: Unpaywall url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/ sourceTypes: Open Access Repository – sequence: 4 dbid: BENPR name: ProQuest Central Database Suite (ProQuest) url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 2218-1989 |
ExternalDocumentID | oai_doaj_org_article_8ecbed7c95b64e63ab09e87007eb0ac2 10.3390/metabo14100565 PMC11509456 A814401620 39452947 10_3390_metabo14100565 |
Genre | Journal Article |
GeographicLocations | Hungary United States--US Germany |
GeographicLocations_xml | – name: Hungary – name: United States--US – name: Germany |
GrantInformation_xml | – fundername: National Research, Development and Innovation Office-NKFIH grantid: K142273 project – fundername: National Research, Development and Innovation Office—NKFIH grantid: K142273 project |
GroupedDBID | 53G 5VS 8FE 8FH AADQD AAFWJ AAYXX AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI CCPQU CITATION DIK GROUPED_DOAJ HCIFZ HYE IAO ITC KQ8 LK8 M48 M7P MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY PQGLB PROAC PUEGO RPM NPM PMFND 7QR 8FD ABUWG AZQEC DWQXO FR3 GNUQQ P64 PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM ADRAZ ADTOC IPNFZ RIG UNPAY |
ID | FETCH-LOGICAL-c507t-96c04efb23af9c1a82e06a34b824c516b0c08b26f972207b71cab7a7c00badd83 |
IEDL.DBID | M48 |
ISSN | 2218-1989 |
IngestDate | Wed Aug 27 01:31:58 EDT 2025 Sun Sep 07 11:12:18 EDT 2025 Tue Sep 30 17:07:27 EDT 2025 Fri Sep 05 00:05:23 EDT 2025 Fri Jul 25 12:02:15 EDT 2025 Tue Jun 17 22:04:33 EDT 2025 Tue Jun 10 21:08:49 EDT 2025 Mon Jul 21 06:05:39 EDT 2025 Wed Oct 01 01:14:51 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | fibroblast growth factor 21 hyperlipidemia levothyroxine thyroid hypothyroidism Hashimoto’s thyroiditis FGF21 |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). cc-by |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c507t-96c04efb23af9c1a82e06a34b824c516b0c08b26f972207b71cab7a7c00badd83 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0009-0000-5303-3082 0000-0002-9791-9288 0000-0002-9286-6471 0000-0003-0439-9867 0000-0001-9761-9595 0000-0002-4909-0065 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/metabo14100565 |
PMID | 39452947 |
PQID | 3120744677 |
PQPubID | 2032362 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_8ecbed7c95b64e63ab09e87007eb0ac2 unpaywall_primary_10_3390_metabo14100565 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11509456 proquest_miscellaneous_3120600632 proquest_journals_3120744677 gale_infotracmisc_A814401620 gale_infotracacademiconefile_A814401620 pubmed_primary_39452947 crossref_primary_10_3390_metabo14100565 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-10-01 |
PublicationDateYYYYMMDD | 2024-10-01 |
PublicationDate_xml | – month: 10 year: 2024 text: 2024-10-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Metabolites |
PublicationTitleAlternate | Metabolites |
PublicationYear | 2024 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | ref_50 Biondi (ref_46) 2019; 40 Planavila (ref_8) 2013; 4 Bonde (ref_28) 2014; 55 Yu (ref_6) 2011; 57 Adams (ref_25) 2010; 285 Ates (ref_40) 2016; 174 Zhang (ref_26) 2015; 224 Semba (ref_21) 2013; 27 ref_19 Mraz (ref_16) 2009; 71 Gereben (ref_45) 2008; 29 Xiao (ref_29) 2015; 100 Salgado (ref_22) 2021; 118 Murphy (ref_23) 2013; 25 Lee (ref_32) 2013; 60 Tellechea (ref_43) 2021; 72 Kharitonenkov (ref_2) 2005; 115 Wang (ref_13) 2018; 41 ref_24 Fiorenza (ref_51) 2024; 5 Shen (ref_17) 2013; 12 Wang (ref_33) 2016; 31 Chow (ref_18) 2013; 33 Nason (ref_7) 2018; 67 Yong (ref_20) 2023; 45 Domouzoglou (ref_27) 2014; 155 ref_36 ref_35 Ueland (ref_48) 2022; 187 Stein (ref_15) 2010; 59 Bookout (ref_3) 2010; 24 ref_30 Mutsnaini (ref_11) 2019; 68 Lewis (ref_1) 2019; 30 ref_39 ref_38 ref_37 Jung (ref_10) 2017; 31 Bande (ref_31) 2019; 23 Tan (ref_5) 2011; 60 Ren (ref_52) 2021; 10 (ref_49) 2022; 54 Wang (ref_9) 2018; 56 ref_47 ref_44 Fu (ref_34) 2014; 2 Wang (ref_12) 2015; 49 Giannakou (ref_41) 2018; 7 Zhang (ref_14) 2008; 57 ref_4 Hussien (ref_42) 2018; 9 |
References_xml | – volume: 4 start-page: 2019 year: 2013 ident: ref_8 article-title: Fibroblast growth factor 21 protects against cardiac hypertrophy in mice publication-title: Nat. Commun. doi: 10.1038/ncomms3019 – volume: 7 start-page: 990 year: 2018 ident: ref_41 article-title: The effect of obesity and dietary habits on oxidative stress in Hashimoto’s thyroiditis publication-title: Endocr. Connect. doi: 10.1530/EC-18-0272 – volume: 25 start-page: 180 year: 2013 ident: ref_23 article-title: Increased responses to the actions of fibroblast growth factor 21 on energy balance and body weight in a seasonal model of adiposity publication-title: J. Neuroendocrinol. doi: 10.1111/j.1365-2826.2012.02383.x – ident: ref_35 doi: 10.3389/fimmu.2019.02349 – volume: 56 start-page: 301 year: 2018 ident: ref_9 article-title: Improving hyperglycemic effect of FGF-21 is associated with alleviating inflammatory state in diabetes publication-title: Int. Immunopharmacol. doi: 10.1016/j.intimp.2018.01.048 – volume: 68 start-page: 351 year: 2019 ident: ref_11 article-title: Fibroblast growth factor 21 deficiency aggravates obesity-induced hypothalamic inflammation and impairs thermogenic response publication-title: Inflamm. Res. doi: 10.1007/s00011-019-01222-2 – volume: 9 start-page: 113 year: 2018 ident: ref_42 article-title: Levothyroxine improves Paraoxonase (PON-1) serum levels in patients with primary hypothyroidism: Case-control study publication-title: J. Adv. Pharm. Technol. Res. doi: 10.4103/japtr.JAPTR_298_18 – volume: 31 start-page: 134 year: 2017 ident: ref_10 article-title: The U-shaped relationship between fibroblast growth factor 21 and microvascular complication in type 2 diabetes mellitus publication-title: J. Diabetes Complicat. doi: 10.1016/j.jdiacomp.2016.10.017 – ident: ref_24 doi: 10.3389/fneur.2017.00079 – ident: ref_37 doi: 10.3390/medicina57121374 – volume: 187 start-page: 293 year: 2022 ident: ref_48 article-title: Novel inflammatory biomarkers in thyroid eye disease publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-22-0247 – volume: 23 start-page: 557 year: 2019 ident: ref_31 article-title: Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism and its Association with Body Fat Percentage publication-title: Indian J. Endocrinol. Metab. doi: 10.4103/ijem.IJEM_273_19 – ident: ref_38 doi: 10.3389/fendo.2022.915394 – volume: 31 start-page: 94 year: 2016 ident: ref_33 article-title: Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism publication-title: Eur. J. Intern. Med. doi: 10.1016/j.ejim.2016.03.028 – volume: 60 start-page: 2758 year: 2011 ident: ref_5 article-title: Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: Relationship with plasma FGF21 and body adiposity publication-title: Diabetes doi: 10.2337/db11-0672 – ident: ref_4 doi: 10.3389/fendo.2022.873699 – volume: 49 start-page: 385 year: 2015 ident: ref_12 article-title: A novel function for fibroblast growth factor 21: Stimulation of NADPH oxidase-dependent ROS generation publication-title: Endocrine doi: 10.1007/s12020-014-0502-9 – volume: 27 start-page: 397 year: 2013 ident: ref_21 article-title: Elevated serum fibroblast growth factor 21 is associated with hypertension in community-dwelling adults publication-title: J. Hum. Hypertens. doi: 10.1038/jhh.2012.52 – volume: 174 start-page: 727 year: 2016 ident: ref_40 article-title: The impact of levothyroxine sodium treatment on oxidative stress in Hashimoto’s thyroiditis publication-title: Eur. J. Endocrinol. doi: 10.1530/EJE-15-1061 – volume: 5 start-page: 101629 year: 2024 ident: ref_51 article-title: Weight-loss maintenance is accompanied by interconnected alterations in circulating FGF21-adiponectin-leptin and bioactive sphingolipids publication-title: Cell Rep. Med. doi: 10.1016/j.xcrm.2024.101629 – volume: 60 start-page: 977 year: 2013 ident: ref_32 article-title: Plasma FGF21 levels are increased in patients with hypothyroidism independently of lipid profile publication-title: Endocr. J. doi: 10.1507/endocrj.EJ12-0427 – ident: ref_44 doi: 10.3389/fendo.2023.1187725 – volume: 24 start-page: 2050 year: 2010 ident: ref_3 article-title: Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse publication-title: Mol. Endocrinol. doi: 10.1210/me.2010-0142 – volume: 285 start-page: 14078 year: 2010 ident: ref_25 article-title: Thyroid hormone regulates hepatic expression of fibroblast growth factor 21 in a PPARalpha-dependent manner publication-title: J. Biol. Chem. doi: 10.1074/jbc.C110.107375 – volume: 224 start-page: 289 year: 2015 ident: ref_26 article-title: Thyroid hormone receptor regulates most genes independently of fibroblast growth factor 21 in liver publication-title: J. Endocrinol. doi: 10.1530/JOE-14-0440 – volume: 57 start-page: 1246 year: 2008 ident: ref_14 article-title: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans publication-title: Diabetes doi: 10.2337/db07-1476 – ident: ref_39 doi: 10.1186/1471-2458-7-220 – volume: 59 start-page: 33 year: 2010 ident: ref_15 article-title: Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia publication-title: Metabolism doi: 10.1016/j.metabol.2009.07.003 – volume: 33 start-page: 2454 year: 2013 ident: ref_18 article-title: Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors publication-title: Arter. Thromb. Vasc. Biol. doi: 10.1161/ATVBAHA.113.301599 – volume: 2 start-page: 1 year: 2014 ident: ref_34 article-title: Relationship between fibroblast growth factor 21 and thyroid stimulating hormone in healthy subjects without components of metabolic syndrome publication-title: Fam. Med. Community Health doi: 10.15212/FMCH.2014.0118 – volume: 118 start-page: 154738 year: 2021 ident: ref_22 article-title: FGF21 and Chronic Kidney Disease publication-title: Metabolism doi: 10.1016/j.metabol.2021.154738 – volume: 155 start-page: 2031 year: 2014 ident: ref_27 article-title: Fibroblast growth factor 21 and thyroid hormone show mutual regulatory dependency but have independent actions in vivo publication-title: Endocrinology doi: 10.1210/en.2013-1902 – ident: ref_36 doi: 10.3389/fpubh.2022.1020709 – volume: 100 start-page: 3800 year: 2015 ident: ref_29 article-title: Elevated Serum Fibroblast Growth Factor 21 Levels in Patients with Hyperthyroidism publication-title: J. Clin. Endocrinol. Metab. doi: 10.1210/jc.2015-1797 – volume: 40 start-page: 789 year: 2019 ident: ref_46 article-title: Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders publication-title: Endocr. Rev. doi: 10.1210/er.2018-00163 – volume: 72 start-page: 62 year: 2021 ident: ref_43 article-title: Meta-analytic evidence for increased low-grade systemic inflammation and oxidative stress in hypothyroid patients. Can levothyroxine replacement therapy mitigate the burden? publication-title: Endocrine doi: 10.1007/s12020-020-02484-1 – volume: 29 start-page: 898 year: 2008 ident: ref_45 article-title: Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling publication-title: Endocr. Rev. doi: 10.1210/er.2008-0019 – volume: 45 start-page: 2179336 year: 2023 ident: ref_20 article-title: Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: A meta-analysis publication-title: Ren. Fail. doi: 10.1080/0886022X.2023.2179336 – volume: 30 start-page: 491 year: 2019 ident: ref_1 article-title: Going Back to the Biology of FGF21: New Insights publication-title: Trends Endocrinol. Metab. doi: 10.1016/j.tem.2019.05.007 – volume: 71 start-page: 369 year: 2009 ident: ref_16 article-title: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity publication-title: Clin. Endocrinol. doi: 10.1111/j.1365-2265.2008.03502.x – volume: 54 start-page: 203 year: 2022 ident: ref_49 article-title: FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance publication-title: Horm. Metab. Res. doi: 10.1055/a-1778-4159 – volume: 57 start-page: 691 year: 2011 ident: ref_6 article-title: Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans publication-title: Clin. Chem. doi: 10.1373/clinchem.2010.155184 – ident: ref_30 doi: 10.3389/fendo.2018.00800 – ident: ref_19 doi: 10.1371/journal.pone.0129791 – ident: ref_50 doi: 10.3390/biomedicines12061320 – volume: 12 start-page: 124 year: 2013 ident: ref_17 article-title: Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease publication-title: Cardiovasc. Diabetol. doi: 10.1186/1475-2840-12-124 – volume: 55 start-page: 2408 year: 2014 ident: ref_28 article-title: Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans publication-title: J. Lipid Res. doi: 10.1194/jlr.M051664 – ident: ref_47 doi: 10.3390/cancers11081154 – volume: 115 start-page: 1627 year: 2005 ident: ref_2 article-title: FGF-21 as a novel metabolic regulator publication-title: J. Clin. Invest. doi: 10.1172/JCI23606 – volume: 10 start-page: 3258 year: 2021 ident: ref_52 article-title: Retrospective analysis of factors associated with serum levels of fibroblast growth factor-21 in patients with diabetes publication-title: Ann. Palliat. Med. doi: 10.21037/apm-21-525 – volume: 67 start-page: 1806-P year: 2018 ident: ref_7 article-title: Glucagon Regulates Energy Balance via FGF-21 Signaling in the Brain publication-title: Diabetes doi: 10.2337/db18-1806-P – volume: 41 start-page: 73 year: 2018 ident: ref_13 article-title: FGF-21 Plays a Crucial Role in the Glucose Uptake of Activated Monocytes publication-title: Inflammation doi: 10.1007/s10753-017-0665-7 |
SSID | ssj0000605701 |
Score | 2.2875435 |
Snippet | Background/Objectives: Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis... Fibroblast growth factor 21 (FGF21) is a hormonal regulator of lipid and glucose metabolism exerting protection against atherosclerosis by multiple actions on... |
SourceID | doaj unpaywall pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 565 |
SubjectTerms | Adipose tissue Age Arteriosclerosis Atherosclerosis Blood vessels Body fat C-reactive protein Cardiovascular disease Cholesterol Diabetes Enzyme-linked immunosorbent assay FGF21 fibroblast growth factor 21 Fibroblast growth factors Fibroblasts Glucose Glucose metabolism Growth factors Hashimoto’s thyroiditis Health aspects High density lipoprotein Hormones hyperlipidemia Hypothalamus Hypothyroidism Kinases levothyroxine Lipid metabolism Lipoproteins Liver diseases Measurement Metabolic disorders Obesity Physiological aspects Regression analysis Statistical analysis thyroid Thyroid diseases Thyroid gland Thyroid hormones Thyroiditis Thyroxine Triglycerides Variables Weight control White people |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELbQXuCCgOWny4IGCQGXaB3HcZJjQZSCFoTQrrS3yH9RK22TVZtq6Y3X4Myb8STMxGnVwGEvXGM7cWY-j7-JJzOMvYwzI9KkKiInkb5JJ3VkKpdEKkf6qgonTVcl4vMXNT2Xny7Si71SXxQTFtIDB8Gd5N4a7zJbpEZJrxJteOERZDzzhmvbWV_cxvacqWCDkYfwOGRpTNCvP1n4FqVKUY245aeDXahL1v-vSd7bk_6Ol7y9rq_05lpfXu5tRpN77G7PImEcZn-f3fL1A3Y4rtGDXmzgFXRxnd0H80P267S5BjQJ6wVM0DduDPLlFj6g-93OYNKV2wERwylFD4GuHXxsVzCmQ3Tv4FsoVY_KA7OBs9lm2cwdTJHoUo5_mNfwNSRmXQF90YUp1WZC7Te_f_xcbftT2iTAO-AjCBfL5jtSWyCT1cUp4M0fsvPJ-7N306gvzRBZJJBtVCjLpa-MSHRV2FjnwnOlE2lyIW0aK8Mtz41QVZEJwTOTxVabTGeWc4MWNU8esYMaJ_qEgUYHSCvrjEYmKmRuijzmVUGxXCledSP2equq8ipk4CjRcyGllkOljthb0uSuF2XO7i4gnsoeT-VNeMLHEQ5KWt-obKv73xRwspQpqxzndBweK8FH7HjQE9elHTZvkVT2dmFVJjFKAz3wLBuxF7tmGkmxbrVv1qGPIuqIc3kcgLd7paSgg3KJo_MBJAfvPGyp57MuazhRfxytRuzNDr03CPTofwj0KbsjkAiGAMhjdtAu1_4ZErnWPO_W7B-8VkvV priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lb9QwELbK9gAXBJRHoCAjIeAS1XEcJzkgtEVdFlRWVdVKvUV-hV2pmyy7WZW98Tc488_4JczksTQgwTW2E9szHn9jT74h5EUQax6FeepbAfBNWKF8ndvQlwnAV5laoessEZ8mcnwuPl5EFztk0v0Lg2GVnU2sDbUtDZ6RH4QBh90OlnX8dvHFx6xReLvapdBQbWoF-6amGLtBdtEkiwHZPTyanJxuT10YoPeYBQ17Ywj-_sHcVTDbGO0IUCDq7U41if_fpvraXvVnHOXNdbFQmyt1eXltkxrdIbdbdEmHjTrcJTuuuEf2hgV41vMNfUnreM_6IH2P_DguryiYivWcjsBnLjXg6Iq-B7e8mtJRnYaH8oAeY1QRVYWlH6oVHeLlurP0tElhD0KlekPPpptlObN0DAAYuf_prKAnDWHriuJJLx1jzibQivLnt--rrj7SKVF4A3wC9WVZfgXIS9GU1fEL8PL75Hx0dPZu7LcpG3wDwLLyU2mYcLnmocpTE6iEOyZVKHTChYkCqZlhieYyT2MO8tRxYJSOVWwY02Bpk_ABGRTQ0UeEKnCMlDRWK0CoXCQ6TQKWpxjjFcFT65FXnaiyRcPMkYFHg0LN-kL1yCFKclsLGbXrB-Xyc9Yu0CxxRjsbmzTSUjgZKs1SB8aMxU4zZTh8DvUgw3UPwjaq_X0BOosMWtkwwWvyQHLmkf1eTVivpl_caVLW2otV9lu7PfJ8W4wtMQaucOW6qSMRUkJfHjaKtx1SmOIFuoDWSU8le2PulxSzac0mji4BtJYeeb3V3v9M6ON_D-EJucUB-jUhj_tkUC3X7ilAt0o_a9fjL_vESKs priority: 102 providerName: ProQuest – databaseName: Unpaywall dbid: UNPAY link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELege4AXBow_HQMdEgJesjmO4ySPAdEVNKYJrdJ4imzHUSvWdFpTTeWJr8Ez34xPwl2SVs1AGq_xObHP57vf2Zc7xl75kRFhUCReLhG-yVxqzxR54KkY4atKcmnqKhGfj9VwJD-dhWdtgCz9C7Nxfx-gO34wdRUyg4IR0VKHt9mWCtFL7rGt0fFJ-pUqx6GN8ijwp8nI-I9OHYtTJ-b_W_1u2J_rsZF3FuWFXl7p8_MNwzPYZoerITfxJt_2F5XZt9-vZXO8eU732b0We0LaCMsDdsuVD9lOWqLfPV3Ca6ijQetj9h3262h2BahIFlMYoEc9M4iyKzhEp70aw6Au0gPChyOKOQJd5vCxmkNKV-8uhy9NgXtccjBLOB0vL2eTHIYIj6kyAExKOGnSuc6BzoFhSBWdUGZmv3_8nK_oKdkS4BvwEyRNOH0ExECKro5uwJc_YqPBh9P3Q68t6OBZhJ2VlyjLpSuMCHSRWF_HwnGlA2liIW3oK8Mtj41QRRIJwSMT-VabSEeWc4N6OA4es16JA33KQKPbpJXNjUb8KmRsktjnRUKCEOLTvM_erBY9u2jydmTo7xD_sy7_--wdycSaivJt1w9wybJ2-2axs8blkU1Co6RTgTY8cajqeOQM11bg50iiMtIKKDZWtz834GApv1aWxnSJ7ivB-2yvQ4m72XabVzKZtdpkngU-cgP99ijqs5frZupJEXKlmy0aGkWAE8fypBHh9ZSChK7XJfaOO8LdmXO3pZyM61zj5DBgb9Vnb9f74AaG7v4_6TN2VyBIbIIj91ivuly45wjyKvOi3eF_AHZWUxQ priority: 102 providerName: Unpaywall |
Title | Low Serum Fibroblast Growth Factor 21 Level and Its Altered Regulation by Thyroid Hormones in Patients with Hashimoto’s Thyroiditis on Levothyroxine Substitution |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39452947 https://www.proquest.com/docview/3120744677 https://www.proquest.com/docview/3120600632 https://pubmed.ncbi.nlm.nih.gov/PMC11509456 https://doi.org/10.3390/metabo14100565 https://doaj.org/article/8ecbed7c95b64e63ab09e87007eb0ac2 |
UnpaywallVersion | publishedVersion |
Volume | 14 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Colorado Digital library customDbUrl: eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: KQ8 dateStart: 20110101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: DIK dateStart: 20110101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: RPM dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central Database Suite (ProQuest) customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 2218-1989 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2218-1989 dateEnd: 20250831 omitProxy: true ssIdentifier: ssj0000605701 issn: 2218-1989 databaseCode: M48 dateStart: 20111101 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1fb9MwELfG9gAvCBiwwqgOCQ1eAo6TOMkDQh1aKWirpmmVxlNkOy6t1CZdm2rrG1-DZ74Zn4S7JK0WmODV_2L7zne_sy93jL1yQy0Cbxg7qY_wzU995ehh6jkyQvgq49TXZZaIk77sDfwvF8HFFlu78tYbuLjVtKN8UoP55O315eoDHvj3ZHGiyf5uagvcMHJYRG0eHMwuHUoqRY-vdYaNO2wHFZVLofVPavRfCWoEK9ytQjneMlJDVZUR_f-W2zcU159OlXeX2UytrtRkckNjdR-w-zXUhE7FGw_Zls0esd1Ohmb2dAUHUDp_lrfqu-zncX4FKDeWU-iiAZ1rBNUFfEIbvRhBt8zJA8KFY3IxApWl8LlYQIde2m0KZ1U-e6Qw6BWcj1bzfJxCD9EwJQKAcQanVfTWBdC1L_QogROySP7r-4_Fuj3FVgIcAT9BzDPPrxH_Asm10pkBB3_MBt2j8489p87f4BhEmYUTS8N9O9TCU8PYuCoSlkvl-ToSvglcqbnhkRZyGIdC8FCHrlE6VKHhXKPYjbwnbDvDie4xUGglKWlSrRCuCj_SceTyYUwOXwGWpi32ek2qZFaF6UjQvCGiJk2ittghUXLTisJrlwX5_FtSn9YkskbbNDRxoKVvpac0jy1KNh5azZUR-Dnig4TYEoltVP0vA06WwmklnYjezF0peIvtN1ri4TXN6jUnJWveTzwXdwPN9DBssZebaupJDnGZzZdVG0n4EufytGK8zZK8mF7TfewdNViyseZmTTYelaHFyT7A3rLF3my49z8b-uzfS3jO7gnEgZX_4z7bLuZL-wJxXKHbbOfwqH961i7vQdrl2cSyQf-08_U3MEZRTw |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9FAuCCiPQIFF4nWxul7ba_tQoRQaEppGVdVKvZnd9bqJ1NghcRRy429w5n_wY_glzPgRapDg1Kv34V3P-NtvdmdnCHlh-4p7ThJasQv0zY1daakkdiwRAH0VYeyqIkvE0VD0ztyP5975BvlR34VBt8oaEwugjjONe-S7js1htYPf2n87_Wxh1ig8Xa1TaMgqtUK8V4QYqy52HJrVEky4-V7_Pcj7Jefdg9N3PavKMmBp4EK5FQrNXJMo7sgk1LYMuGFCOq4KuKs9WyimWaC4SEKfwxCUb2upfOlrxhSAQ-BAvzfIJtAO7rbI5v7B8PhkvcvDwFrwmV1Gi3SckO1OTA7SRe9KoB5eYzUskgb8vTRcWRv_9NvcWqRTuVrKy8sri2L3NrlVsVnaKdXvDtkw6V2y3UnBkp-s6Cta-JcWG_fb5PsgW1KApsWEdsFGzxTw9px-mGXLfES7Rdofym06QC8mKtOY9vM57eBhvonpibmo8oxRtaKno9UsG8e0B4Qbcw3QcUqPywCxc4o7y7SHOaJAC7OfX7_N6_oYvolCD_AK1M9Z9gUoNkXoLPwloPN75OxahHeftFIY6ENCJRhiUuhYSWDE3A1UGNgsCdGnzIOncZu8rkUVTctIIBFYUCjUqCnUNtlHSa5rYQTv4kE2u4gqQIgCo5WJfR16SrhGOFKx0AB4Mt8oJjWH16EeRIgzIGwtq-sSMFiM2BV1AjyWtwVnbbLTqAn4oJvFtSZFFT7No99_U5s8XxdjS_S5S022KOsIpLAwlgel4q2n5IR4YO9C66Chko05N0vS8aiIXo4mCLQWbfJmrb3_-aCP_j2FZ2Srd3o0iAb94eFjcpMD7SzdLXdIK58tzBOgjbl6Wv2blHy6bjj4BYrkhdw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtNAEF6VVAIuCCg_gQKLxN_Fynptr-1DhVLakNAQRVUr9WZ21-smUmOHxFHIjdfgzNvwGDwJM7YTapDg1Kv3x7ue8bff7M7OEPLC9hX3nCS0Yhfomxu70lJJ7FgiAPoqwthVRZaIjwPRPXU_nHlnW-TH-i4MulWuMbEA6jjTuEfecmwOqx381n4rqdwihgedt9PPFmaQwpPWdToNWaVZiPeKcGPVJY8js1qCOTff6x2A7F9y3jk8ede1qowDlgZelFuh0Mw1ieKOTEJty4AbJqTjqoC72rOFYpoFiosk9DkMR_m2lsqXvmZMAVAEDvR7jWz7ThiwBtnePxwMjzc7PgwsB5_ZZeRIxwlZa2JykDR6WgIN8WorY5FA4O9l4tI6-acP541FOpWrpby4uLRAdm6TWxWzpe1SFe-QLZPeJTvtFKz6yYq-ooWvabGJv0O-97MlBZhaTGgH7PVMAYfP6ftZtsxHtFOkAKLcpn30aKIyjWkvn9M2HuybmB6b8yrnGFUrejJazbJxTLtAvjHvAB2ndFgGi51T3GWmXcwXBRqZ_fz6bb6uj6GcKPQAr0BdnWVfgG5ThNHCdwI6v0dOr0R490kjhYE-JFSCUSaFjpUEdszdQIWBzZIQ_cs8eBo3yeu1qKJpGRUkAmsKhRrVhdok-yjJTS2M5l08yGbnUQUOUWC0MrGvQ08J1whHKhYaAFLmG8Wk5vA61IMIMQeErWV1dQIGi9G7onaAR_S24KxJdms1ASt0vXitSVGFVfPo95_VJM83xdgS_e9Sky3KOgLpLIzlQal4myk5IR7eu9A6qKlkbc71knQ8KiKZozkCrUWTvNlo738-6KN_T-EZuQ6wEPV7g6PH5CYHBlp6Xu6SRj5bmCfAIHP1tPo1Kfl01WjwC5c4ihY |
linkToUnpaywall | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1fb9MwELege4AXBow_HQMdEgJesjmO4ySPAdEVNKYJrdJ4imzHUSvWdFpTTeWJr8Ez34xPwl2SVs1AGq_xObHP57vf2Zc7xl75kRFhUCReLhG-yVxqzxR54KkY4atKcmnqKhGfj9VwJD-dhWdtgCz9C7Nxfx-gO34wdRUyg4IR0VKHt9mWCtFL7rGt0fFJ-pUqx6GN8ijwp8nI-I9OHYtTJ-b_W_1u2J_rsZF3FuWFXl7p8_MNwzPYZoerITfxJt_2F5XZt9-vZXO8eU732b0We0LaCMsDdsuVD9lOWqLfPV3Ca6ijQetj9h3262h2BahIFlMYoEc9M4iyKzhEp70aw6Au0gPChyOKOQJd5vCxmkNKV-8uhy9NgXtccjBLOB0vL2eTHIYIj6kyAExKOGnSuc6BzoFhSBWdUGZmv3_8nK_oKdkS4BvwEyRNOH0ExECKro5uwJc_YqPBh9P3Q68t6OBZhJ2VlyjLpSuMCHSRWF_HwnGlA2liIW3oK8Mtj41QRRIJwSMT-VabSEeWc4N6OA4es16JA33KQKPbpJXNjUb8KmRsktjnRUKCEOLTvM_erBY9u2jydmTo7xD_sy7_--wdycSaivJt1w9wybJ2-2axs8blkU1Co6RTgTY8cajqeOQM11bg50iiMtIKKDZWtz834GApv1aWxnSJ7ivB-2yvQ4m72XabVzKZtdpkngU-cgP99ijqs5frZupJEXKlmy0aGkWAE8fypBHh9ZSChK7XJfaOO8LdmXO3pZyM61zj5DBgb9Vnb9f74AaG7v4_6TN2VyBIbIIj91ivuly45wjyKvOi3eF_AHZWUxQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Low+Serum+Fibroblast+Growth+Factor+21+Level+and+Its+Altered+Regulation+by+Thyroid+Hormones+in+Patients+with+Hashimoto%E2%80%99s+Thyroiditis+on+Levothyroxine+Substitution&rft.jtitle=Metabolites&rft.au=Berta%2C+Eszter&rft.au=Halmi%2C+S%C3%A1ndor&rft.au=Moln%C3%A1r%2C+Istv%C3%A1n&rft.au=Hutkai%2C+D%C3%A1vid&rft.date=2024-10-01&rft.pub=MDPI+AG&rft.eissn=2218-1989&rft.volume=14&rft.issue=10&rft.spage=565&rft_id=info:doi/10.3390%2Fmetabo14100565&rft.externalDBID=HAS_PDF_LINK |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2218-1989&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2218-1989&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2218-1989&client=summon |